2019-09-13
2019-09-13
Plenary Hall
Ballroom A
Ballroom B
Exhibit and Poster Hall
2019-09-14
2019-09-14
Plenary Hall
Ballroom A
Ballroom B
Exhibit and Poster Hall
2019-09-15
2019-09-15
Plenary Hall
Ballroom A
Ballroom B
Plenary Hall
Ballroom A
Ballroom B
Exhibit and Poster Hall
Plenary Hall
Ballroom A
Ballroom B
Exhibit and Poster Hall
Plenary Hall
Ballroom A
Ballroom B
07:30
- 08:30
Morning Session 1: MSC therapy; Rationalism vs. Empiricism; How much must we know to test therapies in patients; a Live Debate
Allan B. Dietz, PhD (Chair)
Mayo Clinic, USA
Jacques Galipeau, MD
University of Wisconsin - Madison, USA
William Faubion, MD
Mayo Clinic, USA
07:30
- 08:30
Q&O Track 1: Media Fills
Adrian Gee, PhD
Baylor College of Medicine, USA
Aisha Khan, MS, MBA
University of Miami, USA
08:45
- 10:15
Plenary 1: Mesenchymal and Progenitor Stem Cells: Results from the Clinic and the Future of Living Drugs
Allan B. Dietz, PhD (Chair)
Mayo Clinic, USA
Gil Van Bokkelen, PhD
Athersys, USA
Etienne Sokal, MD, PhD
Promethera, Belgium
10:45
- 12:15
Oral Abstracts Session 1
Patrick Hanley, PhD (Chair)
Children’s National Health System, USA
10:45
- 12:15
Workshop 1: ISCT-NAVRMA Joint Session – Veterinary Medicine in Developing Cell-Based Therapies and Bioengineering Approach for Human Clinical Use
Daniel Weiss, MD, PhD (Chair)
University of Vermont, USA
Tracey Webb, DVM, PhD (Chair)
Colorado State University, USA
Andrew Hoffman, DVM, DVSc, DACVIM
University of Pennsylvania School of Veterinary Medicine, USA
Kyla Ortved, DVM, PhD
University of Pennsylvania School of Veterinary Medicine, USA
Aimee Colbath, VMD, PhD, DACVS-LA
Michigan State University College of Veterinary Medicine, USA
Dori Borjesson, BA, DVM, MPVM, PhD
UC Davis School of Veterinary Medicine, USA
10:45
- 12:15
Q&O Track 2: Managing the Mushrooming Growth in Cell and Gene
Lynn O’Donnell, PhD (Chair)
Ohio State University, James Cancer Hospital Columbus, USA
12:30
- 13:30
Corporate Tutorial Hosted by Fresenius-Kabi
13:45
- 15:15
Plenary 2: iPSC and Pluripotent Stem Cells – True Replacement Cell Therapies
Robert Deans, PhD (Chair)
BlueRock Therapeutics, USA
Dan Kaufman, MD, PhD
University of California San Diego, USA
Stephanie Protze, PhD
University of Toronto, Canada
Robert Deans, PhD
15:30
- 17:00
Q&O Track 3: Stability
Karl Stasko, MPH (Chair)
Dana-Farber Cancer Institute, Cell Manipulation Core Facility, USA
Karl Stasko, MPH
Dana-Farber Cancer Institute, Cell Manipulation Core Facility, USA
Jackie Damen, PhD
Senior Scientific Advisor, Hematopoiesis, Canada
Rosemarie Bell, B.App.Sc Micro/Biochem MASM,
QIMR Berghofer Medical Research Institute/ Q-Gen Cell Therapeutics, Australia
15:30
- 17:00
Workshop 2: ISCT Presidential Task Force – Regulatory Aspects of Unproven Cell and Gene Therapies in North America
Laertis Ikonomou, PhD (Chair)
Boston University, USA
Peter Marks, MD, PhD
Center for Biologics Evaluation and Research, FDA, USA
Lynne Boxer, DVM
Center for Veterinary Medicine, FDA, USA
Ajay Kuriyan, MD, MS
Department of Ophthalmology, University of Rochester Medical Center, USA
Kristin Matthews, PhD
Rice University's Baker Institute for Public Policy, USA
15:30
- 17:00
Workshop 3: Gene Replacement Therapy Using Adult Stem Cells
Mitchell Cairo, MD (Chair)
New York Medical College, USA
Mitchell Cairo, MD
New York Medical College, USA
Jeffrey Medin, PhD
Medical College of Wisconsin, USA
Paul Orchard, MD
University of Minnesota, USA
17:00
- 18:00
Corporate Symposium
07:30
- 08:30
Q&O Track 4: Current Clinical Development Regulatory Guidance – Context and Implications
Kurt Gunter, MD (Chair)
Cell Medica Inc., USA
Peiman Hematti, MD
University of Wisconsin-Madison School of Medicine and Public Health, USA
Cynthia Molina
Triumvira, USA
07:30
- 08:30
Morning Session 2 – Meet the Experts: Cellular Therapy Quality and Operations
Lizette Caballero, BS, MLS(ASCP)CM (Chair)
UCSF Blood and Marrow Transplant Lab, USA
Paul Eldridge, PhD
UNC Lineberger Comprehensive Cancer Center, USA
Olive Sturtevant, MHP, MT(ASCP)SBB
Dana-Farber CMCF, USA
07:30
- 08:30
Morning Session 3 – Meet the Experts: CAR T and other Cell “Vehicles”
Sarah Nikiforow, MD, PhD (Chair)
Dana-Farber Cancer Institute, USA
08:45
- 10:15
Plenary 3: Redirecting Immune Cells – T and NK cells aside from canonical CARs
Sarah Nikiforow, MD, PhD (Chair)
Dana-Farber Cancer Institute, USA
Denis-Claude Roy, MD, FRCPC
Hopital Maisonneuve-Rosemont, Canada
Lisa Butterfield, PhD
University of Pittsburgh Department of Medicine, USA
Sumithira Vasu, MBBS
Comprehensive Cancer Center, Ohio State University, USA
10:45
- 12:15
Oral Abstracts Session 2
10:45
- 12:15
Advanced Practice Professionals* (APP) Track Session 1: Management of CRS toxicity or other reactions related to CAR therapy
Valkal Bhatt, PharmD, BCOP, BCPS (Chair)
Memorial Sloan Kettering Cancer Center, USA
Christina Bachmeier, PharmD, BCOP
Moffitt Cancer Center, USA
Rebecca Gonzalez, PharmD, BCOP
Moffitt Cancer Center, USA
Marian Dam, DNP, APRN
Moffitt Cancer Center, USA
10:45
- 12:15
Workshop 4: Optimizing Clinical Trials in Cellular Therapy
Denis-Claude Roy, MD, FRCPC (Chair)
Hopital Maisonneuve-Rosemont, Canada
Lauralyn McIntyre, MD, FRCPC, MSc
Ottawa Hospital Research Institute, Canada
Sarah Nikiforow, MD, PhD
Dana-Farber Cancer Institute, USA
Steven Devine, MD
CIBMTR, USA
13:45
- 15:15
Q&O Track 5: ISCT-ASFA Joint Session – Current Concepts in Cell Collections: HPCs, CAR-T & Regulatory Oversight
Joseph Schwartz, MD, PhD (Co-Chair)
Columbia University, USA
Lizette Caballero, BS, MLS(ASCP)CM (Co-Chair)
UCSF Blood and Marrow Transplant Lab, USA
Donald Siegel, PhD, MD
Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, USA
Anand Padmanabhan, MD, PhD
Blood Center of Wisconsin, USA
Yvette Tanhehco, PhD, MD, MS
Columbia University Irving Medical Center, USA
13:45
- 15:15
Workshop 5: Engineering to Control Cell Environment during Processing
Erika Trauzzi (Chair)
Berkeley Lights Inc., USA
James Lim, PhD
Xcell Biosciences Inc., USA
Peter Beemiller
Berkeley Lights Inc., USA
Angelo Cardoso, MD, PhD
City of Hope, USA
13:45
- 15:15
Advanced Practice Professionals* (APP) Track Session 2: Responsibilities of the Investigator and the Lab in the investigation, communication and reporting of Adverse Events
Valkal Bhatt, PharmD, BCOP, BCPS (Chair)